NO20001601D0 - Genterapitilnærminger for Õ tilføre apolipoprotein A-1- agonister og deres anvendelse for Õ behandle dyslipidemiske forstyrrelser - Google Patents
Genterapitilnærminger for Õ tilføre apolipoprotein A-1- agonister og deres anvendelse for Õ behandle dyslipidemiske forstyrrelserInfo
- Publication number
- NO20001601D0 NO20001601D0 NO20001601A NO20001601A NO20001601D0 NO 20001601 D0 NO20001601 D0 NO 20001601D0 NO 20001601 A NO20001601 A NO 20001601A NO 20001601 A NO20001601 A NO 20001601A NO 20001601 D0 NO20001601 D0 NO 20001601D0
- Authority
- NO
- Norway
- Prior art keywords
- apoa
- agonists
- apolipoprotein
- native
- inject
- Prior art date
Links
- 102000005666 Apolipoprotein A-I Human genes 0.000 title abstract 11
- 108010059886 Apolipoprotein A-I Proteins 0.000 title abstract 11
- 239000000556 agonist Substances 0.000 title abstract 3
- 238000013459 approach Methods 0.000 title abstract 2
- 230000001258 dyslipidemic effect Effects 0.000 title 1
- 238000001415 gene therapy Methods 0.000 title 1
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 208000032928 Dyslipidaemia Diseases 0.000 abstract 1
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract 1
- 206010040070 Septic Shock Diseases 0.000 abstract 1
- 230000002068 genetic effect Effects 0.000 abstract 1
- 230000003278 mimic effect Effects 0.000 abstract 1
- 208000037803 restenosis Diseases 0.000 abstract 1
- 230000036303 septic shock Effects 0.000 abstract 1
- 230000002483 superagonistic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/775—Apolipopeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Diabetes (AREA)
- Physics & Mathematics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Biotechnology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Optics & Photonics (AREA)
- Toxicology (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Vascular Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/940,136 US6518412B1 (en) | 1997-09-29 | 1997-09-29 | Gene therapy approaches to supply apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
| PCT/US1998/020329 WO1999016409A2 (en) | 1997-09-29 | 1998-09-28 | Gene therapy approaches to supply apolipoprotein a-i agonists and their use to treat dyslipidemic disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20001601D0 true NO20001601D0 (no) | 2000-03-28 |
| NO20001601L NO20001601L (no) | 2000-05-26 |
Family
ID=25474297
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20001601A NO20001601L (no) | 1997-09-29 | 2000-03-28 | Genterapitilnærminger for Õ tilføre apolipoprotein A-1- agonister og deres anvendelse for Õ behandle dyslipidemiske forstyrrelser |
Country Status (17)
| Country | Link |
|---|---|
| US (4) | US6518412B1 (no) |
| EP (1) | EP1039934B1 (no) |
| JP (1) | JP2003525565A (no) |
| KR (1) | KR100650975B1 (no) |
| CN (1) | CN100345588C (no) |
| AT (1) | ATE323510T1 (no) |
| AU (1) | AU758307B2 (no) |
| CA (1) | CA2304814A1 (no) |
| DE (1) | DE69834267T2 (no) |
| ES (1) | ES2263221T3 (no) |
| HU (1) | HU225821B1 (no) |
| IL (1) | IL135324A0 (no) |
| NO (1) | NO20001601L (no) |
| NZ (1) | NZ503720A (no) |
| PL (1) | PL193662B1 (no) |
| RU (1) | RU2222545C2 (no) |
| WO (1) | WO1999016409A2 (no) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6518412B1 (en) * | 1997-09-29 | 2003-02-11 | Jean-Louis Dasseux | Gene therapy approaches to supply apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
| US6004925A (en) * | 1997-09-29 | 1999-12-21 | J. L. Dasseux | Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
| JP4794707B2 (ja) * | 1998-11-17 | 2011-10-19 | ソニー株式会社 | 端末装置、課金システム、データ処理方法 |
| AU2001245622A1 (en) * | 2000-03-13 | 2001-09-24 | Amgen Inc. | Apo-a-i regulation of t-cell signaling |
| US7144862B2 (en) * | 2000-08-24 | 2006-12-05 | The Regents Of The University Of California | Orally administered peptides to ameliorate atherosclerosis |
| US7723303B2 (en) * | 2000-08-24 | 2010-05-25 | The Regents Of The University Of California | Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response |
| US7199102B2 (en) * | 2000-08-24 | 2007-04-03 | The Regents Of The University Of California | Orally administered peptides synergize statin activity |
| US6664230B1 (en) * | 2000-08-24 | 2003-12-16 | The Regents Of The University Of California | Orally administered peptides to ameliorate atherosclerosis |
| US8568766B2 (en) | 2000-08-24 | 2013-10-29 | Gattadahalli M. Anantharamaiah | Peptides and peptide mimetics to treat pathologies associated with eye disease |
| US7166578B2 (en) | 2000-08-24 | 2007-01-23 | The Regents Of The University Of California | Orally administered peptides synergize statin activity |
| US7148197B2 (en) * | 2000-08-24 | 2006-12-12 | The Regents Of The University Of California | Orally administered small peptides synergize statin activity |
| US7470659B2 (en) * | 2001-12-07 | 2008-12-30 | The Regents Of The University Of California | Methods to increase reverse cholesterol transport in the retinal pigment epithelium (RPE) and Bruch's membrane (BM) |
| US6930085B2 (en) * | 2002-04-05 | 2005-08-16 | The Regents Of The University Of California | G-type peptides to ameliorate atherosclerosis |
| WO2005068020A1 (en) * | 2004-01-02 | 2005-07-28 | Advanced Cardiovascular Systems, Inc. | High-density lipoprotein coated medical devices |
| AU2005287004B2 (en) * | 2004-09-16 | 2011-03-17 | The Regents Of The University Of California | G-type peptides and other agents to ameliorate atherosclerosis and other pathologies |
| ES2346771T3 (es) | 2004-10-15 | 2010-10-20 | The Government Of The Usa As Represented By The Secretary Of The Department Of Health And Human Serv | Peptidos con multiples dominios a-helicoidales anfipaticos y procedimientos para su uso. |
| US7579319B2 (en) | 2004-12-06 | 2009-08-25 | The Regents Of The University Of California | Methods for improving the structure and function of arterioles |
| US20080293639A1 (en) * | 2005-04-29 | 2008-11-27 | The Regents Of The University Of California | Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response |
| CA2653840A1 (en) * | 2006-06-01 | 2007-12-06 | Institut De Cardiologie De Montreal | Use of a peptide/phospholipid complex acting as a reverse lipid transport agonist for treatment of valvular stenosis |
| US20080206142A1 (en) * | 2006-06-16 | 2008-08-28 | Lipid Sciences, Inc. | Novel Peptides That Promote Lipid Efflux |
| US20080199398A1 (en) * | 2006-06-16 | 2008-08-21 | Brewer H Bryan | Novel Peptides That Promote Lipid Efflux |
| US20080227686A1 (en) * | 2006-06-16 | 2008-09-18 | Lipid Sciences, Inc. | Novel Peptides that Promote Lipid Efflux |
| KR101523108B1 (ko) * | 2006-08-17 | 2015-05-26 | 더 유에이비 리서치 파운데이션 | 면역원성 ｐｃｐａ 폴리펩티드 및 이의 용도 |
| US20080138284A1 (en) * | 2006-09-26 | 2008-06-12 | Lipid Sciences, Inc. | Novel Peptides That Promote Lipid Efflux |
| JP2010537638A (ja) | 2007-08-28 | 2010-12-09 | ユーエービー リサーチ ファウンデーション | 合成アポリポ蛋白質ｅ模倣ポリペプチドおよび使用方法 |
| EP2682400B1 (en) * | 2007-08-28 | 2017-09-20 | Uab Research Foundation | Synthetic apolipoprotein E mimicking polypeptides and methods of use |
| US7985728B1 (en) | 2007-09-20 | 2011-07-26 | Abbott Cardiovascular Systems Inc. | Sustained release of Apo A-I mimetic peptides and methods of treatment |
| US9173890B2 (en) | 2007-09-20 | 2015-11-03 | Abbott Cardiovascular Systems Inc. | Sustained release of Apo A-I mimetic peptides and methods of treatment |
| US8101565B2 (en) * | 2007-09-20 | 2012-01-24 | Abbott Cardiovascular Systems Inc. | Sustained release of Apo A-I mimetic peptides and methods of treatment |
| US7985727B1 (en) | 2007-09-20 | 2011-07-26 | Abbott Cardiovascular Systems Inc. | Apo A-I mimetic peptides and methods of treatment |
| US8044021B2 (en) * | 2007-09-20 | 2011-10-25 | Abbott Cardiovascular Systems Inc. | Sustained release of apo A-I mimetic peptides and methods of treatment |
| WO2009129263A1 (en) * | 2008-04-15 | 2009-10-22 | The Government Of The Usa As Represented By The Secretary Of The Department Of Health & Human Serv. | Peptides promoting lipid efflux via abca1 and activating a lipoprotein lipase |
| EP2939683B1 (en) | 2009-02-16 | 2017-01-04 | Cerenis Therapeutics Holding SA | Apolipoprotein A-I Mimics |
| US8176412B2 (en) * | 2009-08-25 | 2012-05-08 | International Business Machines Corporation | Generating formatted documents |
| RU2013112562A (ru) * | 2010-08-30 | 2014-10-10 | Ф. Хоффманн-Ля Рош Аг | Тетранектин-аполипопротеин а-i, содержащие его липидные частицы и его применение |
| WO2012109162A1 (en) | 2011-02-07 | 2012-08-16 | Cerenis Therapeutics Holding S.A. | Lipoprotein complexes and manufacturing and uses thereof |
| WO2012162392A1 (en) | 2011-05-23 | 2012-11-29 | Timothy Hla | Endothelium protective materials and methods of use |
| EP2748191A1 (en) | 2011-08-25 | 2014-07-02 | F.Hoffmann-La Roche Ag | Shortened tetranectin-apolipoprotein a-i fusion protein, a lipid particle containing it, and uses thereof |
| CN104250288B (zh) * | 2013-06-28 | 2018-02-27 | 清华大学 | 两亲性α螺旋自组装肽及其应用 |
| CN106488987A (zh) | 2014-05-02 | 2017-03-08 | 塞勒尼斯医疗控股公司 | Hdl疗法标志物 |
| EP3189069B1 (en) | 2014-07-31 | 2024-10-23 | UAB Research Foundation | Apoe mimetic peptides and higher potency to clear plasma cholesterol |
| US12257352B2 (en) * | 2016-06-20 | 2025-03-25 | The Regents Of The University Of Michigan | Compositions and methods for delivery of biomacromolecule agents |
| CN115300609A (zh) * | 2021-05-08 | 2022-11-08 | 西湖大学 | 缺氧诱导脂滴相关蛋白(hilpda)在预防或治疗高血脂相关疾病中的应用 |
| WO2025128566A1 (en) * | 2023-12-13 | 2025-06-19 | University Of Kentucky Research Foundation | Synthetic high-density lipoprotein and method for treating sepsis and related conditions |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH621479A5 (no) | 1977-08-05 | 1981-02-13 | Battelle Memorial Institute | |
| CA1173360A (en) | 1979-06-22 | 1984-08-28 | Jurg Schrank | Pharmaceutical preparations |
| DE3241102A1 (de) | 1982-11-06 | 1984-05-10 | A. Nattermann & Cie GmbH, 5000 Köln | Imidazolylalkylthienyl-tetrahydropyridazine und verfahren zu ihrer herstellung |
| US4643988A (en) | 1984-05-15 | 1987-02-17 | Research Corporation | Amphipathic peptides |
| US4880635B1 (en) | 1984-08-08 | 1996-07-02 | Liposome Company | Dehydrated liposomes |
| US4857319A (en) | 1985-01-11 | 1989-08-15 | The Regents Of The University Of California | Method for preserving liposomes |
| EP0644897B1 (en) | 1992-06-12 | 1998-09-16 | N.V. Innogenetics S.A. | New peptides and proteins, process for their preparation and their use as cholesterol acceptors |
| US5674855A (en) | 1992-08-12 | 1997-10-07 | The Rogosin Institute | Methods and compositions useful in prophylaxis and therapy of endotoxin related conditions |
| SE9203753D0 (sv) | 1992-12-11 | 1992-12-11 | Kabi Pharmacia Ab | Expression system for producing apolipoprotein ai-m |
| US5643757A (en) * | 1994-03-21 | 1997-07-01 | American Cyanamid Company | High yield production of human apolipoprotein A1 in E. coli. |
| WO1995027512A2 (en) * | 1994-04-11 | 1995-10-19 | Baylor College Of Medicine | Compositions and methods for gene therapy to treat disease |
| RU2043116C1 (ru) * | 1994-05-04 | 1995-09-10 | Александр Иванович Арчаков | Пептид апов-рецептора, ответственный за связывание липопротеинов низкой плотности |
| FR2723741A1 (fr) * | 1994-08-16 | 1996-02-23 | Fournier Sca Lab | Peptides inhibiteurs de la proteine de transfert des esters de cholesterol et leur utilisation en therapeutique |
| FR2734568B1 (fr) | 1995-05-22 | 1997-06-20 | Rhone Poulenc Rorer Sa | Nouveaux variants de l'apolipoproteine |
| EP0853480B1 (en) * | 1995-09-09 | 2003-01-08 | F. Hoffmann-La Roche Ag | Use of a thienotriazolodiazepine to increase apolipoprotein a-i levels |
| US6518412B1 (en) * | 1997-09-29 | 2003-02-11 | Jean-Louis Dasseux | Gene therapy approaches to supply apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
-
1997
- 1997-09-29 US US08/940,136 patent/US6518412B1/en not_active Expired - Fee Related
-
1998
- 1998-09-28 IL IL13532498A patent/IL135324A0/xx unknown
- 1998-09-28 PL PL98358529A patent/PL193662B1/pl unknown
- 1998-09-28 RU RU2000111526/04A patent/RU2222545C2/ru not_active IP Right Cessation
- 1998-09-28 AT AT98950742T patent/ATE323510T1/de not_active IP Right Cessation
- 1998-09-28 WO PCT/US1998/020329 patent/WO1999016409A2/en not_active Ceased
- 1998-09-28 JP JP2000513549A patent/JP2003525565A/ja not_active Withdrawn
- 1998-09-28 NZ NZ503720A patent/NZ503720A/xx unknown
- 1998-09-28 DE DE69834267T patent/DE69834267T2/de not_active Expired - Fee Related
- 1998-09-28 KR KR1020007003407A patent/KR100650975B1/ko not_active Expired - Fee Related
- 1998-09-28 EP EP98950742A patent/EP1039934B1/en not_active Expired - Lifetime
- 1998-09-28 CN CNB988116502A patent/CN100345588C/zh not_active Expired - Fee Related
- 1998-09-28 AU AU96714/98A patent/AU758307B2/en not_active Ceased
- 1998-09-28 ES ES98950742T patent/ES2263221T3/es not_active Expired - Lifetime
- 1998-09-28 HU HU0003924A patent/HU225821B1/hu unknown
- 1998-09-28 CA CA002304814A patent/CA2304814A1/en not_active Abandoned
-
2000
- 2000-03-28 NO NO20001601A patent/NO20001601L/no unknown
-
2002
- 2002-10-29 US US10/283,599 patent/US6844327B2/en not_active Expired - Fee Related
-
2004
- 2004-11-16 US US10/991,217 patent/US7250407B2/en not_active Expired - Fee Related
-
2007
- 2007-06-18 US US11/764,522 patent/US20080050351A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| HU225821B1 (en) | 2007-10-29 |
| DE69834267D1 (de) | 2006-05-24 |
| HUP0003924A3 (en) | 2005-12-28 |
| CA2304814A1 (en) | 1999-04-08 |
| NZ503720A (en) | 2002-10-25 |
| CN100345588C (zh) | 2007-10-31 |
| WO1999016409A2 (en) | 1999-04-08 |
| KR20010030806A (ko) | 2001-04-16 |
| EP1039934A1 (en) | 2000-10-04 |
| US6844327B2 (en) | 2005-01-18 |
| DE69834267T2 (de) | 2007-01-04 |
| US7250407B2 (en) | 2007-07-31 |
| JP2003525565A (ja) | 2003-09-02 |
| IL135324A0 (en) | 2001-05-20 |
| US20080050351A1 (en) | 2008-02-28 |
| US6518412B1 (en) | 2003-02-11 |
| CN1303298A (zh) | 2001-07-11 |
| PL193662B1 (pl) | 2007-03-30 |
| AU758307B2 (en) | 2003-03-20 |
| EP1039934B1 (en) | 2006-04-19 |
| EP1039934A4 (en) | 2002-11-27 |
| NO20001601L (no) | 2000-05-26 |
| AU9671498A (en) | 1999-04-23 |
| HUP0003924A2 (hu) | 2001-01-29 |
| PL358529A1 (en) | 2004-08-09 |
| ES2263221T3 (es) | 2006-12-01 |
| KR100650975B1 (ko) | 2006-11-29 |
| ATE323510T1 (de) | 2006-05-15 |
| US20030208059A1 (en) | 2003-11-06 |
| US20050148513A1 (en) | 2005-07-07 |
| RU2222545C2 (ru) | 2004-01-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20001601D0 (no) | Genterapitilnærminger for Õ tilføre apolipoprotein A-1- agonister og deres anvendelse for Õ behandle dyslipidemiske forstyrrelser | |
| ES2525677T3 (es) | Celulasas, genes que las codifican y usos de las mismas | |
| DE69942365D1 (de) | Gezielte zufuhr von pharmazeutischen agenzien zu verletzten geweben | |
| CY1116385T1 (el) | Αντινοηματικη διαμορφωση της εκφρασης της απολιποπρωτεινης β | |
| NO20001600D0 (no) | Apolipoprotein A-1-agonister og deres anvendelse for Õ behandle dyslipidemiske forstyrrelser | |
| ATE302267T1 (de) | Transgenes kaninchen, dass ein funktionelles menschliches lipoprotein(a) exprimiert | |
| DE3880739D1 (de) | Expression von menschlichem proapolipoprotein a-1. | |
| NO20001599L (no) | Apolipoprotein A-1 agonister og deres anvendelse for Õ behandle dyslipidemiske forstyrrelser | |
| GB0202556D0 (en) | Novel Protein | |
| ATE307886T1 (de) | Nukleotidsequenzen, proteine, medikamente und diagnoseagentien zur anwendung in krebsbehandlung | |
| BR0209551A (pt) | Promotor de gene especìfico de folha de café | |
| PT815233E (pt) | NOVAS CITOCINAS AVIÁRIAS E SEQUjNCIAS GENÉTICAS QUE AS CODIFICAM | |
| ATE332379T1 (de) | Menschliche dnase resistent gegen actininhibitoren | |
| ATE488592T1 (de) | Auf antibiotikum basierendes genregulationssystem | |
| FR2773079B1 (fr) | Cible de traitement de l'atherosclerose, de l'obesite et du diabete de type ii | |
| ATE325812T1 (de) | Menschliches, gebärmutterkrebs-spezifisches suppressorprotein, für das protein kodieres polynukleotid, mit dem polynukleotid transformierte zelle und verfahren zur unterdrückung der proliferation von krebszellen unter verwendung des expressionsvektors | |
| ATE382637T1 (de) | Rezeptor-tyrosine-kinase gene | |
| DK1673391T3 (da) | Modificeret cDNA til höje ekspressionsniveauer af faktor VIII og dens derivater | |
| ATE387494T1 (de) | Hitzelabile desoxyribonuklease i-varianten |